A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A, Hernandez-Collazo Y, Lee G, Boughan K, Tomlinson B, Gallogly M, Metheny L, Bajor D, Selfridge J, Saltzman J, Lazarus H, de Lima M, Wald D.
Otegbeye F, et al. Among authors: metheny l.
Transplant Cell Ther. 2022 May;28(5):250.e1-250.e8. doi: 10.1016/j.jtct.2022.02.008. Epub 2022 Feb 14.
Transplant Cell Ther. 2022.
PMID: 35172204
Free PMC article.
Clinical Trial.